An FDA panel will meet on June 28 and vote on whether empagliflozin (Jardiance) reduces the risk of cardiovascular death in high-risk patients, Reuters reports. When the FDA approved empagliflozin in 2014 to treat patients with type 2 diabetes, the agency asked the drug’s manufacturers (Eli Lilly & Co. and Boehringer Ingelheim) to conduct a trial to prove the medication did not increase the risk of heart problems.
The companies published the results in January and showed that the drug decreased the risk of death from MI, the risk of death from any cause and the combined risk of cardiac death, non-fatal MIs and non-fatal strokes.
Read the story below:
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.